Proteostasis Therapeutics, Inc.

117 articles about Proteostasis Therapeutics, Inc.

• Proteostasis Selected to Join European Consortium to Pioneer Personalized Medicine in Cystic Fibrosis

  2/27/2019

   Proteostasis Therapeutics, Inc. (NASDAQ: PTI), a clinical stage biopharmaceutical company dedicated to the discovery and development of groundbreaking therapies to treat cystic fibrosis (CF) and other diseases caused by dysfunctional protein processing, today announced it has been invited to join the HIT-CF Europe,

• Proteostasis Therapeutics to Present at the 8th Annual SVB Leerink Global Healthcare Conference

  2/20/2019

  Proteostasis Therapeutics, Inc., announced that Marija Zecevic, Ph.D., the Company's Chief Commercial Officer, will present at the 8th Annual SVB Leerink Global Healthcare Conference on Wednesday, February 27, 2019 at 1:00 p.m. ET at the Lotte New York Palace.

• 

  BioSpace Movers and Shakers: Feb. 8

  2/8/2019

  In this week's edition of Movers and Shakers, biopharma companies tap executives to serve in various leadership roles.

• Proteostasis Therapeutics Appoints Emmanuel Dulac and Kim Drapkin to Board of Directors

  2/6/2019

  Proteostasis Therapeutics, Inc. announced that Emmanuel Dulac, PharmD, Ph.D., and Kim Cobleigh Drapkin, CPA, have been appointed to the Company's Board of Directors.

• Proteostasis Therapeutics Provides Clinical Enrollment Update

  12/20/2018

  Proteostasis Therapeutics, Inc. (NASDAQ:PTI), a clinical stage biopharmaceutical company dedicated to the discovery and development of groundbreaking therapies to treat cystic fibrosis (CF) and other diseases caused by dysfunctional protein processing, today provided a clinical enrollment update.

• Proteostasis Therapeutics Announces Global License Agreement with Genentech

  12/17/2018

  Proteostasis Therapeutics, Inc. (NASDAQ:PTI), a clinical stage biopharmaceutical company dedicated to the discovery and development of groundbreaking therapies to treat cystic fibrosis (CF) and other diseases caused by dysfunctional protein processing, today announced a worldwide, exclusive license agreement with Genentech, a member of the Roche Group, for rights to potential therapeutic small molecule modulators of an undisclosed target within the proteostasis network.

• 

  Genentech Licenses Non-CF Compound From Proteostasis in $100 Million-Plus Deal

  12/17/2018

  Proteostasis Therapeutics, based in Boston, signed a worldwide, exclusive license deal with Genentech for rights to a possible small molecule modulator within the proteostasis network.

• Proteostasis Therapeutics to Participate in Upcoming Investor Conferences

  11/21/2018

  Proteostasis is a clinical stage biopharmaceutical company dedicated to the discovery and development of groundbreaking therapies to treat cystic fibrosis and other diseases caused by dysfunctional protein processing

• 

  SVB Financial Group to Buy Venture Capital Firm Leerink, a Top 10 Underwriter for Biotech IPOs

  11/14/2018

  Leerink Holdings is the Boston-based parent company of Leerink Partners. Leerink Partners is an investment bank focused on healthcare and life sciences.
• 

  AbbVie Takes Over Galapagos Cystic Fibrosis Collaboration Instead of Walking Away

  10/25/2018

  What is AbbVie thinking? That’s the question of many investors, analysts and industry watchers as the Chicago-based AbbVie decided to buy up researcher partner Galapagos' cystic fibrosis portfolio instead of walking away.

• Proteostasis Therapeutics Prices Public Offering of 11,000,000 Shares of Its Common Stock

  10/24/2018

  Proteostasis Therapeutics, Inc. announced today that it has priced an underwritten public offering of 11,000,000 shares of its common stock at a price to the public of $6.75 per share.

• Proteostasis Therapeutics Announces Proposed Public Offering of 9,000,000 shares of Its Common Stock

  10/22/2018

  Proteostasis Therapeutics, Inc. announced today that it intends to offer and sell, subject to market and other conditions, 9,000,000 shares of its common stock in an underwritten public offering.

• 

  Proteostasis Therapeutics' Double and Triple-Combo CF Drugs Possible Threat to Vertex Dominance

  10/19/2018

  Proteostasis Therapeutics announced positive preliminary data from its ongoing Phase I clinical trial of PTI-808 and PTI-801 in cystic fibrosis (CF). Despite it being an early-stage trial and preliminary data, company shares exploded upward by 301 percent, with more than 44 million shares trading...

• Proteostasis Therapeutics Announces Positive Preliminary Results from Proprietary Doublet in Cystic Fibrosis Patients

  10/17/2018

  Proteostasis Therapeutics, Inc. announces positive preliminary results from three doublet cohorts of the Company's ongoing Phase 1.

• Proteostasis Therapeutics to Present at the Cantor Global Healthcare Conference

  9/27/2018

  Proteostasis Therapeutics, Inc., announced that Marija Zecevic, Ph.D., the Company's Chief Operating Officer, will present at the Cantor Global Healthcare Conference on Wednesday, October 3, 2018 at 3:25 p.m. ET at the InterContinental New York Barclay.

• Proteostasis Announces Positive Data from Ongoing Phase 1 Study of PTI-801 in Cystic Fibrosis Patients on Background Orkambi® Therapy

  6/6/2018

  Proteostasis Therapeutics, Inc. announced positive results from the Company's ongoing 14-day dosing study of PTI-801 in CF patients on background Orkambi® (lumacaftor/ivacaftor) therapy.

• Proteostasis Announces Presentations at the 41st European Cystic Fibrosis Society Conference

  6/1/2018

  Proteostasis Therapeutics, Inc. announced that data from the Company's CF clinical development programs will be presented during two panel presentations at the 41st European Cystic Fibrosis Society (ECFS) Conference.

• Proteostasis Therapeutics to Present at the Jefferies 2018 Global Healthcare Conference

  5/31/2018

  Proteostasis Therapeutics, Inc. announced that Po-Shun Lee, M.D., the Company's Chief Medical Officer, will present at the Jefferies 2018 Global Healthcare Conference.

• Proteostasis Announces Formation of Independent Steering Committee of Leading Experts to Advise on the Global Phase 3 Clinical Development Program for PTI-428 in Cystic Fibrosis

  5/8/2018

  Proteostasis Therapeutics, Inc. (NASDAQ:PTI), a clinical stage biopharmaceutical company dedicated to the discovery and development of groundbreaking therapies to treat cystic fibrosis (CF) and other diseases caused by dysfunctional protein processing, announced today the formation of an independent Steering Committee to guide the Phase 3 global clinical development program for PTI-428.

• Proteostasis Receives Endorsement from the Cystic Fibrosis Foundation's Therapeutic Development Network for the Study of the Company's Amplifier, PTI-428, in CF Subjects on Background Symdeko™ Therapy

  4/17/2018

  Phase 2 Study of PTI-428 + Symdeko Planned to Initiate in 3Q'18.